. Author manuscript; available in PMC: 2013 Jan 1.

Published in final edited form as: Behav Brain Res. 2011 Sep 17;226(1):224–234. doi: 10.1016/j.bbr.2011.09.022

Table 2.

Mean distance traveled in 30 min on baseline and test day following a microinjection pretreatment in the LDT or IC and IP injection of saline or MA.

Microinjection site	IP	Microinjection pretreatment	Baseline activity^*	Test day activity^*, ^†	N
LDT	Saline	aCSF	2547 (720)	2968 (1435)^a	5
		1 nM OXO	3415 (657)	2336 (1326)^a	6
		10 nM OXO	5207 (569)	1269 (1148)	8
	2 mg/kg	aCSF	3535 (720)	10114 (1453)^a	5
	MA	1 nM OXO	3736 (569)	9890 (1148)^a	8
		10 nM OXO	3946 (609)	5004 (1228)	7
IC	Saline	aCSF	3920 (713)	3234 (985)	7
		1 nM OXO	3691 (713)	3662 (985)	7
		10 nM OXO	5084 (843)	3647 (1165)	5
	2 mg/kg	aCSF	3950 (943)	9149 (1303)^b	4
	MA	1 nM OXO	4216 (770)	9811 (1064)^b	6
		10 nM OXO	3800 (713)	8146 (985)^b	7

Data expressed as distance (cm ± SEM).

^†

In mice that received microinjection pretreatment into the LDT, simple main effects analysis of a significant day × IP interaction revealed test activity to be significantly different from baseline in mice that received IP saline (p = 0.001) or MA (p = 0.001).

Simple main effects analysis of a significant day × pretreatment interaction revealed test day activity was significantly increased compared to baseline in mice pretreated with aCSF (p = 0.01) or 1 nM OXO (p < 0.05).

Test day activity was significantly increased in mice that received microinjection pretreatment in the inferior colliculus and IP MA (IC; p < 0.0001).